Diagnexia has announced an exclusive partnership with Artera to bring the ArteraAI Prostate Biopsy Assay to the UK.
This collaboration represents a major step forward in bringing advanced personalised treatment plans to patients through the first multimodal AI risk stratification tool for those with localised prostate cancer. Through this integration, Diagnexia and Artera deliver a unique proposition: a fast, accurate, and cost-effective solution to some of the greatest challenges in prostate cancer treatment personalisation.
The ArteraAI Prostate Biopsy Assay is a powerful digital biomarker solution that combines patient clinical data - such as age, PSA levels, and T-stage - with AI interpretation of biopsy slides. This multimodal approach eliminates the need for additional invasive procedures or expensive molecular tests, providing clinicians with actionable insights. It is the first AI-enabled test of its kind to be recommended by the National Comprehensive Cancer Network (NCCN) in the USA for localised prostate cancer.
Key features include:
Risk assessment: estimates the likelihood of distant metastasis and prostate cancer-specific mortality over 10 years
Therapy guidance: predicts the benefit of short-term androgen deprivation therapy (ADT) when combined with radiotherapy
Personalised insights: enhances decision-making for active surveillance and likelihood of future adverse pathology.
The collaboration between Diagnexia and Artera addresses critical challenges in prostate cancer treatment planning that impact both clinicians and patients, including long wait times for test results, difficulty predicting disease progression, the high costs associated with molecular tests, and the frequent occurrence of inconclusive molecular test reports due to insufficient tissue quantity or quality.
For patients, the ArteraAI Prostate Biopsy Assay offers a fast, non-invasive, and affordable risk stratification tool, with the added reassurance of expert secondary consultations from Diagnexia’s global network of pathologists.
For clinicians, this partnership provides access to a revolutionary AI tool that integrates seamlessly into existing workflows, offering data-backed insights to guide personalised treatment plans.
Donal O'Shea, CEO of Diagnexia commented: “This partnership highlights the transformative potential of AI in revolutionising personalised cancer care. As the first and only global digital pathology service, Diagnexia has been at the forefront of digital innovation from the start. We see this new wave of digital biomarkers as a pivotal advancement, and by combining our expertise with Artera’s innovative technology, we aim to transform digital diagnostics services in the UK and beyond.”
The ArteraAI Prostate Biopsy Assay, will soon be available for order through Diagnexia, providing clinicians in the UK with an advanced AI-powered diagnostic tool for prostate cancer risk stratification.